


Dose Finding by the Continual Reassessment Method



Ying Kuen Cheung

**Dose Finding
by the Continual
Reassessment Method**

Chapman & Hall/CRC Biostatistics Series

Editor-in-Chief

Shein-Chung Chow, Ph.D.

Professor

*Department of Biostatistics and Bioinformatics
Duke University School of Medicine
Durham, North Carolina*

Series Editors

Byron Jones

Senior Director

*Statistical Research and Consulting Centre
(IPC 193)
Pfizer Global Research and Development
Sandwich, Kent, U.K.*

Jen-pei Liu

Professor

*Division of Biometry
Department of Agronomy
National Taiwan University
Taipei, Taiwan*

Karl E. Peace

Georgia Cancer Coalition

Distinguished Cancer Scholar

Senior Research Scientist and

Professor of Biostatistics

Jiann-Ping Hsu College of Public Health

Georgia Southern University

Statesboro, Georgia

Bruce W. Turnbull

Professor

School of Operations Research

and Industrial Engineering

Cornell University

Ithaca, New York

Chapman & Hall/CRC Biostatistics Series

Adaptive Design Theory and Implementation Using SAS and R, Mark Chang

Advances in Clinical Trial Biostatistics, Nancy L. Geller

Applied Statistical Design for the Researcher, Daryl S. Paulson

Basic Statistics and Pharmaceutical Statistical Applications, Second Edition, James E. De Muth

Bayesian Adaptive Methods for Clinical Trials, Scott M. Berry, Bradley P. Carlin, J. Jack Lee, and Peter Muller

Bayesian Methods for Measures of Agreement, Lyle D. Broemeling

Bayesian Missing Data Problems: EM, Data Augmentation and Noniterative Computation, Ming T. Tan, Guo-Liang Tian, and Kai Wang Ng

Bayesian Modeling in Bioinformatics, Dipak K. Dey, Samiran Ghosh, and Bani K. Mallick

Causal Analysis in Biomedicine and Epidemiology: Based on Minimal Sufficient Causation, Mikel Aickin

Clinical Trial Data Analysis using R, Ding-Geng (Din) Chen and Karl E. Peace

Clinical Trial Methodology, Karl E. Peace and Ding-Geng (Din) Chen

Computational Methods in Biomedical Research, Ravindra Khattree and Dayanand N. Naik

Computational Pharmacokinetics, Anders Källén

Data and Safety Monitoring Committees in Clinical Trials, Jay Herson

Design and Analysis of Animal Studies in Pharmaceutical Development, Shein-Chung Chow and Jen-pei Liu

Design and Analysis of Bioavailability and Bioequivalence Studies, Third Edition, Shein-Chung Chow and Jen-pei Liu

Design and Analysis of Clinical Trials with Time-to-Event Endpoints, Karl E. Peace

Difference Equations with Public Health Applications, Lemuel A. Moyé and Asha Seth Kapadia

DNA Methylation Microarrays: Experimental Design and Statistical Analysis, Sun-Chong Wang and Arturas Petronis

DNA Microarrays and Related Genomics Techniques: Design, Analysis, and Interpretation of Experiments, David B. Allison, Grier P. Page, T. Mark Beasley, and Jode W. Edwards

Dose Finding by the Continual Reassessment Method, Ying Kuen Cheung

Elementary Bayesian Biostatistics, Lemuel A. Moyé

Frailty Models in Survival Analysis, Andreas Wienke

Handbook of Regression and Modeling: Applications for the Clinical and Pharmaceutical Industries, Daryl S. Paulson

Measures of Interobserver Agreement and Reliability, Second Edition, Mohamed M. Shoukri

Medical Biostatistics, Second Edition, A. Indrayan

Meta-Analysis in Medicine and Health Policy, Dalene Generalized Linear Models: A Bayesian Perspective, Dipak K. Dey, Sujit K. Ghosh, and Bani K. Mallick

Monte Carlo Simulation for the Pharmaceutical Industry: Concepts, Algorithms, and Case Studies, Mark Chang

Multiple Testing Problems in Pharmaceutical Statistics, Alex Dmitrienko, Ajit C. Tamhane, and Frank Bretz

Sample Size Calculations in Clinical Research, Second Edition, Shein-Chung Chow, Jun Shao, and Hansheng Wang

Statistical Design and Analysis of Stability Studies, Shein-Chung Chow

Statistical Methods for Clinical Trials, Mark X. Norleans

Statistics in Drug Research: Methodologies and Recent Developments, Shein-Chung Chow and Jun Shao

Statistics in the Pharmaceutical Industry, Third Edition, Ralph Buncher and Jia-Yeong Tsay

Translational Medicine: Strategies and Statistical Methods, Dennis Cosmatos and Shein-Chung Chow

This page intentionally left blank

Chapman & Hall/CRC Biostatistics Series

Dose Finding by the Continual Reassessment Method

Ying Kuen Cheung

Columbia University

New York, New York, USA



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

A CHAPMAN & HALL BOOK

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2011 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works
Version Date: 20111012

International Standard Book Number-13: 978-1-4200-9152-6 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Preface

Despite its poor statistical properties, the 3+3 algorithm remains the most commonly used dose finding method in phase I clinical trials today. However, as clinicians begin to realize the important role of dose finding in the drug development process, there is an increasing openness to “novel” methods proposed in the past two decades. In particular, the continual reassessment method (CRM) and its variations have drawn much attention in the medical community. To ride on this momentum and overcome the status quo in the phase I practice, it is critical for us (statisticians) to be able to design a trial using the CRM in a timely and reproducible manner. This is the impetus to writing a detailed exposition on the calibration of the CRM for applied statisticians who need to deal with dose finding in phase I trials while having many other duties to attend to.

A natural approach to such a writing project is to write a *how-to* book. By the time I started this book project in the summer of 2008, I had helped design half a dozen CRM trials (three of which are included as examples in this book). In retrospect, I found some general patterns of how I calibrated the CRM parameters in these trials. These patterns, characterized collectively as a trial-and-error approach in Chapter 7, worked well in the sense that they gave reasonable operating characteristics to a design. However, it was time-consuming (weeks of simulation) and would require an intimate understanding of the CRM (I wrote a PhD dissertation on the CRM). I realized that some automation and step-by-step guidelines in this calibration process would be crucial and appreciated if the CRM was to be used on a regular basis by a wide group of statisticians. Chapters 7–10 try to address this need by breaking a CRM design into a list of design parameters, each of which is to be calibrated in a prescribed manner.

Despite my pragmatic approach, I hope this book is not only a cookbook. I intend to provide a full coverage of the CRM. This book includes a comprehensive review of the CRM (Chapter 3) and elaborate properties of the CRM (Chapters 5 and 6). While this book is based on my previous publications on the CRM, I have introduced new material so as to present the CRM under a unified framework (Chapter 4). These chapters serve as the theoretical foundation of the calibration techniques presented in the later chapters. I also reflect on what *not* to do with the CRM (Chapter 12) and when *not* to use the CRM (Chapter 13). From a practical viewpoint, these *not-to* chapters are as important as, if not more important than, the *how-to* chapters, because they avoid abuses and pitfalls in applying the CRM. I believe that using the CRM in a wrong way or in the wrong trial is no better, or arguably worse, than falling back to the 3+3 algorithm. The time-to-event aspect of the toxicity endpoint has been a

recurring concern in my previous CRM trials, and so is included as an extension of the CRM (Chapter 11). All in all, while this is not intended to be a cookbook, the inclusion of materials is based on their practical relevance.

This book does not cover dose finding in all possible clinical settings. In fact, it has a singular focus on the simplest and the most common phase I trial setting, where the study endpoint is defined as a binary outcome and the subjects are assumed to come from a homogeneous population. I make no mention of the concerns with multiple toxicity and the gradation of severe toxicities. The topic of individualized dosing is omitted. While some basic ideas of dose finding using both efficacy and toxicity are outlined in Chapter 13, the discussion is brief and does not do full justice to this fast-growing area. All these are important topics in which I am intellectually interested. Their omission, however, is mainly due to my limited *practical* experience in dealing with these “nonstandard” situations in real dose finding studies; dealing with these issues simply from a *methodological* and *theoretical* viewpoint does not fit my intent of writing a practical book (although I think such a book is interesting in its own right and hope someone more qualified than I will deliver it). I do have a word or two to add from a methodological and theoretical viewpoint here, if not already alluded to in the book’s final chapter (Section 14.4, to be precise). First, a complete theoretical framework is crucial for these nonstandard methods to be successfully translated into actual practice. In this book, I try to explicate possible pathological behaviors (e.g., incoherence and rigidity) of some CRM modifications for the simplest setting; it is reasonable to infer that these pathologies will multiply for methods more complex than the CRM for the more complicated clinical settings. Solid theoretical investigation will help us navigate the potential pitfalls. I also hope the theoretical framework developed in this book for the simplest case will prove useful when extended to the complicated settings. Second, and more specifically, I think stochastic approximation offers partial solutions (albeit mostly theoretical) to many of these nonstandard dose finding settings. This is why I close this book with a chapter where I try to connect and compare the CRM with the rich stochastic approximation literature.

The last points I just made give a hint about my methodological and theoretical interests. I hope that this book will in some way simulate research in the CRM and general dose finding methods, despite its practical nature. As I try to present the CRM and the dose finding criteria at a rigorous level, and to cover the CRM literature as comprehensively as possible, I also hope this book can serve as an introduction for those interested in doing research in this area. I taught a course on sequential experimentation at Columbia University from an early unpublished version of this book. This final manuscript is, in turn, adapted from the course notes, and is suitable for use in a course on sequential experimentation or clinical trials.

There are several statistics books on dose finding. The two most popular ones are the edited volumes by Chevret [26] and by Ting [105]. Both give surveys of dose finding methods and are good introductions to the dose finding literature. By comparison, this book is a single-authored work on a specific dose finding method, which I think is necessary if we are to get down to the nuts and bolts of the method.

By writing a book on the CRM, I do not imply that it is the best method out there.

In fact, for the dose finding objective considered here, it is unlikely that there is one method that is best or optimal in a *uniform* sense. While some methods may work best under certain scenarios according to some criterion, the others are optimal under a different criterion. There have been numerous proposals in the last two decades. These proposals can be good alternatives against the 3+3 algorithm as long as they are calibrated properly. And, the CRM is one of these methods. Furthermore, the CRM has been worked out and discussed in the statistical and medical literature so extensively that I believe we are getting close to translating this method into practice. This book hopefully will be a catalyst in this translational process.

I owe a debt of gratitude to Tom Cook, Bin Cheng, and an anonymous reviewer who have been generous with their time and given detailed comments on earlier versions of the book. I am grateful for Jimmy Duong for his help to maintain the R package ‘dfcrm’ (a companion software with this book). I would also like to thank Rick Chappell who introduced me to the CRM and clinical trials when I was a student at University of Wisconsin–Madison. This book would not be possible without his mentoring. Finally, my most heartfelt thanks go to my wife, Amy, for her support and enthusiasm during this writing process.

*New York
October 2010*

This page intentionally left blank

Contents

I	Fundamentals	1
1	Introduction	3
2	Dose Finding in Clinical Trials	7
2.1	The Maximum Tolerated Dose	7
2.2	An Overview of Methodology	10
2.3	Bibliographic Notes	15
2.4	Exercises and Further Results	16
3	The Continual Reassessment Method	17
3.1	Introduction	17
3.2	One-Stage Bayesian CRM	17
3.2.1	General Setting and Notation	17
3.2.2	Dose–Toxicity Model	17
3.2.3	Dose Labels	18
3.2.4	Model-Based MTD	20
3.2.5	Normal Prior on β	21
3.2.6	Implementation in R	21
3.3	Two-Stage CRM	22
3.3.1	Initial Design	22
3.3.2	Maximum Likelihood CRM	23
3.4	Simulating CRM Trials	25
3.4.1	Numerical Illustrations	25
3.4.2	Methods of Simulation	25
3.5	Practical Modifications	27
3.5.1	Dose Escalation Restrictions	27
3.5.2	Group Accrual	28
3.5.3	Stopping and Extension Criteria	30
3.6	Bibliographic Notes	31
3.7	Exercises and Further Results	31

4	One-Parameter Dose–Toxicity Models	33
4.1	Introduction	33
4.2	ψ -Equivalent Models	33
4.3	Model Assumptions [†]	36
4.4	Proof of Theorem 4.1 [†]	40
4.5	Exercises and Further Results	40
5	Theoretical Properties	41
5.1	Introduction	41
5.2	Coherence	41
5.2.1	Motivation and Definitions	41
5.2.2	Coherence Conditions of the CRM	42
5.2.3	Compatibility	43
5.2.4	Extensions	45
5.3	Large-Sample Properties	46
5.3.1	Consistency and Indifference Interval	46
5.3.2	Consistency Conditions of the CRM	48
5.3.2.1	Home Sets	48
5.3.2.2	Least False Parameters	48
5.3.2.3	Main Result	49
5.3.2.4	A Relaxed Condition	49
5.3.3	Model Sensitivity of the CRM	51
5.3.4	Computing Model Sensitivity in R	53
5.4	Proofs [†]	54
5.4.1	Coherence of One-Stage CRM	54
5.4.2	Consistency of the CRM	55
5.5	Exercises and Further Results	56
6	Empirical Properties	57
6.1	Introduction	57
6.2	Operating Characteristics	57
6.2.1	Accuracy Index	57
6.2.2	Overdose Number	59
6.2.3	Average Toxicity Number	59
6.3	A Nonparametric Optimal Benchmark	60
6.4	Exercises and Further Results	62
II	Design Calibration	63
7	Specifications of a CRM Design	65
7.1	Introduction	65
7.2	Specifying the Clinical Parameters	66
7.2.1	Target Rate θ	66
7.2.2	Number of Test Doses K	66
7.2.3	Sample Size N	66

CONTENTS	xiii
7.2.4 Prior MTD v_0 and Starting Dose x_1	67
7.3 A Roadmap for Choosing the Statistical Component	68
7.4 The Trial-and-Error Approach: Two Case Studies	69
7.4.1 The Bortezomib Trial	69
7.4.2 NeuSTART	71
7.4.3 The Case for an Automated Process	73
8 Initial Guesses of Toxicity Probabilities	75
8.1 Introduction	75
8.2 Half-width (δ) of Indifferent Interval	75
8.3 Calibration of δ	77
8.3.1 Effects of δ on the Accuracy Index	77
8.3.2 The Calibration Approach	78
8.3.3 Optimal δ for the Logistic Model	79
8.4 Case Study: The Bortezomib Trial	81
8.5 Exercises and Further Results	87
9 Least Informative Normal Prior	89
9.1 Introduction	89
9.2 Least Informative Prior	89
9.2.1 Definitions	89
9.2.2 Rules of Thumb	91
9.3 Calibration of σ_β	93
9.3.1 Calibration Criteria	93
9.3.2 An Application to the Choice of v_0	93
9.3.3 Optimality Near σ_β^{LI}	95
9.4 Optimal Least Informative Model	97
9.5 Revisiting the Bortezomib Trial	99
10 Initial Design	103
10.1 Introduction	103
10.2 Ordering of Dose Sequences	103
10.3 Building Reference Initial Designs	106
10.3.1 Coherence-Based Criterion	106
10.3.2 Calibrating Compatible Dose Sequences	107
10.3.3 Reference Initial Designs for the Logistic Model	109
10.4 Practical Issues	109
10.4.1 Sample Size Constraint	109
10.4.2 Dose Insertion [†]	112
10.5 Case Study: NeuSTART	113
10.6 Exercises and Further Results	115

III CRM and Beyond	117
11 The Time-to-Event CRM	119
11.1 Introduction	119
11.2 The Basic Approach	119
11.2.1 A Weighted Likelihood	119
11.2.2 Weight Functions	120
11.2.3 Individual Toxicity Risks	122
11.3 Numerical Illustration	123
11.3.1 The Bortezomib Trial	123
11.3.2 Implementation in R	124
11.4 Enrollment Scheduling	125
11.4.1 Patient Accrual	125
11.4.2 Interim Suspensions	127
11.5 Theoretical Properties [†]	129
11.5.1 Real-Time Formulation	129
11.5.2 Real-Time Coherence	129
11.5.3 Consistency	130
11.6 Two-Stage Design	131
11.6.1 Waiting Window	131
11.6.2 Case Study: The Poly E Trial	132
11.7 Bibliographic Notes	135
11.8 Exercises and Further Results	136
12 CRM with Multiparameter Models	139
12.1 Introduction	139
12.2 Curve-Free Methods	139
12.2.1 The Basic Approach	139
12.2.2 Product-of-Beta Prior Distribution	140
12.2.3 Dirichlet Prior Distribution	143
12.2.4 Isotonic Design	144
12.3 Rigidity	146
12.3.1 Illustrations of the Problem	146
12.3.2 Remedy 1: Increase m	147
12.3.3 Remedy 2: Increase Prior Correlations	147
12.4 Two-Parameter CRM [†]	149
12.4.1 The Basic Approach	149
12.4.2 A Rigid Two-Parameter CRM: Illustration	150
12.4.3 Three-Stage Design	151
12.4.4 Continuous Dosage	153
12.5 Bibliographic Notes	154
12.6 Exercise and Further Results	154

13 When the CRM Fails	155
13.1 Introduction	155
13.2 Trade-Off Perspective of MTD	155
13.2.1 Motivation	155
13.2.2 Maximum Safe Dose and Multiple Testing	156
13.2.3 A Sequential Stepwise Procedure	157
13.2.4 Case Study: The ASCENT Trial	159
13.2.5 Practical Notes	161
13.3 Bivariate Dose Finding	162
14 Stochastic Approximation	167
14.1 Introduction	167
14.2 The Past Literature	167
14.2.1 The Robbins-Monro Procedure	167
14.2.2 Maximum Likelihood Recursion	168
14.2.3 Implications on the CRM	169
14.3 The Present Relevance	170
14.3.1 Practical Considerations	170
14.3.2 Dichotomized Data	171
14.3.3 Virtual Observations	174
14.3.4 Quasi-Likelihood Recursion	175
14.4 The Future Challenge	176
14.5 Assumptions on $M(x)$ and $Y(x)^\dagger$	177
14.6 Exercises and Further Results	178
References	179
Index	187

This page intentionally left blank

Part I

Fundamentals

This page intentionally left blank

Introduction

The clinical development of a new drug or a new treatment proceeds through three phases of testing in human subjects. Phase I trials are small studies that evaluate safety and identify a safe dose range of the treatment. Once a dose range is chosen, its therapeutic efficacy will be examined in a phase II trial. Regimens that are shown promising in phase II trials will be moved to multi-institutional phase III clinical trials for randomized comparison to standard treatments. The ultimate goal of this entire process is to translate promising discoveries in the laboratory into new medical procedures that can be used in the general clinical settings. This division of clinical trials, however, may give an oversimplified picture of the actual drug development process. Often, several phase I-II trial sequels of a drug, possibly with minor variations in the treatment schedule and patient populations, are needed before a phase III trial is warranted. This process is necessarily iterative rather than linear, as the phase I-II-III paradigm appears to suggest. In addition, the taxonomy of trials is not universal across disciplines, and may include finer divisions such as phase IA, IB, IIA, and IIB. The recent trend to combine phases of trials, the so-called combined phase I/II trials and seamless phase II/III trials, renders further refinement of the drug development process.

This having been said, the phase I-II-III paradigm provides a conceptual framework for in-depth study of statistical methods. The subject matter of this book is dose finding using the continual reassessment method (CRM). The CRM [78] is among the first model-based designs for phase I cancer trials in which toxicity is the primary study endpoint. The role of toxicity in early-phase cancer trials had long been a subject for discussion in the medical literature [93, 85]. In particular, for cytotoxic drugs, toxicity serves as evidence that the drug has reached a level that does harm not only to the cancer cells but also to a patient's normal organs. In other words, a therapeutic dose is expected to cause a significant amount of severe but reversible toxicities in the cancer patient population. Therefore, a primary goal of phase I cancer trials is to identify the so-called maximum tolerated dose (MTD). For other disorders such as acute stroke and HIV, identifying the MTD is also a primary objective of early-phase safety studies (usually called phase IB trials). In addition, dose finding is important in phase II proof-of-concept trials where the goal is to identify a dose range with demonstrated biological activity. This objective is usually achieved through the estimation of the minimum effective dose (MED) [106, 27]. From a statistical viewpoint,

the MTD in safety studies and the MED in efficacy studies can be formulated in an analogous way. Therefore, this book is relevant to the design of phase I and II dose finding trials. Under the modernized paradigm, the dose finding principles discussed here also address the design issues in the combined phase I/II trials, in which both the safety and the efficacy endpoints are considered as co-primary (cf. Section 13.3).

Another advantage of dividing the drug development process into phases is that by doing so, we can set a clear and manageable benchmark to achieve in a particular study. This entails a clearly defined set of study endpoints and an interpretable study objective. Since clinical trials are conducted in human subjects, each benchmark is to be reached within certain ethical constraints. In particular, in phase I dose finding studies, randomization is not entirely appropriate because it may expose subjects to excessively high and toxic doses without sufficiently testing the lower doses. (Some would also argue randomization exposes subjects to low and inefficacious doses, although this aspect is apparently not as alarming.)

We illustrate these points using a bortezomib dose finding trial [62]. Bortezomib is a proteasome inhibitor with proven activity in lymphoma. In the trial, bortezomib was given in combination with the standard chemotherapy as a first-line treatment for patients with diffuse large B cell or mantle cell non-Hodgkin's lymphoma. Each patient would receive up to six 21-day cycles of the treatment combination. Table 1.1 describes the five dose schedules of bortezomib tested in the trial. The primary safety concerns related to bortezomib were neuropathy, low platelet count, and symptomatic non-neurologic or non-hematologic toxicity. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [71], with grade 3 or higher defined as *dose limiting*. Generally, a grade 3 toxicity is severe but can be resolved by symptomatic treatment, whereas a grade 4 toxicity is irreversible; toxic death due to the treatment is invariably defined as grade 5. The primary endpoint of each patient was the indicator of whether any dose-limiting toxicity (DLT) was experienced at any time during the six cycles. The objective of the trial was to determine the MTD, defined as a dose associated with a 25% DLT rate. Table 1.1 gives the number of patients and the number of DLTs per dose in the bortezomib trial. The data show strong evidence that the highest dose is adequately safe: we pool the observations in dose levels 4 and 5 by assuming an increasing dose-toxicity relationship; based on 1 DLT out of 16 patients, we obtain a 95% confidence upper bound of 0.26 for the DLT probability.

Table 1.1 The bortezomib trial [62]: dose schedules of bortezomib, sample size (n), and the number of DLT (z) at each dose

Level	Dose and schedule within cycle	n	z
1	0.7 mg/m ² on day 1 of each cycle	0	0
2	0.7 mg/m ² on days 1 and 8 of each cycle	0	0
3	0.7 mg/m ² on days 1 and 4 of each cycle	4	0
4	1.0 mg/m ² on days 1 and 4 of each cycle	9	1
5	1.3 mg/m ² on days 1 and 4 of each cycle	7	0

While simple analyses are usually adequate to address the primary scientific questions in a phase I study, the summary statistics in Table 1.1 ignore how the data were collected. Figure 1.1 shows the dose assignments of the trial in chronological order. The trial started at level 3, a dose schedule that the investigators believed to be safe to treat patients. Escalation to the next higher dose occurred after four patients had been followed for several weeks without signs of toxicity, and another escalation took place after three following patients. Shortly after the eighth patient entered the trial at the highest dose, patient 7 at dose level 4 experienced a DLT, thus leading to a deescalation for the ninth patient. Subsequent patients were enrolled in a staggered fashion, allowing months to pass before reescalating to the highest level. A central feature of this dose assignment scheme is its outcome adaptiveness. Specifically, in the bortezomib trial, the dose assignments were made in accordance with the time-to-event continual reassessment method (TITE-CRM), an extension of the CRM to be discussed in Chapter 11. For ethical reasons, most dose finding trials are conducted in an outcome-adaptive manner, so that the dose assignment of the current patient depends on those of the previous patients. As such, the focus of this book is the *design* (as opposed to analysis) of a dose finding study using the CRM and its variants.




Figure 1.1 Dose assignments in the bortezomib trial. Each number indicates a patient: An unmarked number represents the patient's entry time; a number marked with "O" indicates the time when a DLT occurs, and "D" indicates the time of dropout. Vertical positions of some numbers are jittered for clarification.

This book is organized into three parts. Part I (Chapters 2–6) contains the background and introductory material of the CRM. Specifically, Chapter 2 provides the clinical background, outlines the problem of dose finding in the context of several real trial examples, and reviews the dose finding literature. Chapter 3 introduces the basic approach of the CRM and presents its major modifications. The method will be developed along with a description of an R package ‘dferm’. Chapter 4 presents a unified framework for dose–toxicity models used in the CRM. Chapters 5 and 6, respectively, discuss the theoretical and empirical properties of the CRM. The objective of Part I is for the readers to develop a basic understanding of the CRM and be able to implement the method using a simple R code. Readers familiar with the basic CRM methodology are also encouraged to review the materials, as they are reorganized and presented in a unified framework in this book.

Part II (Chapters 7–10) details the calibration process of the CRM based on the notation and the theory introduced in Part I. Chapter 7 introduces a system of design parameters involved in the CRM, and classifies them into two categories: *clinical parameters* and *model parameters*. The subsequent chapters then present fine-tuning techniques of the model parameters: the initial guesses of the toxicity probabilities (Chapter 8), the prior distribution of the model parameter (Chapter 9), and the initial design of a two-stage CRM (Chapter 10). The objective of Part II is for the readers to develop the ability to design a “good” CRM trial within a reasonable timeline.

Part III (Chapters 11–14) contains a variety of advanced topics related to the CRM. Chapter 11 presents the TITE-CRM to deal with situations in which the toxicity outcome is defined with respect to a nontrivial duration. Chapter 12 gives a critical review of CRM using multiparameter models. Chapter 13 considers situations where the CRM is an inappropriate design, and puts forward some alternatives. Chapter 14 connects the CRM and modern dose finding trials to the large literature of stochastic approximation. The objective of Part III is to stimulate further research in the CRM and general dose finding methodology.

The materials in this book are presented at a level that requires college algebra and some basic calculus concepts. Sections marked with “+” in the table of contents contain technical details that may be skipped without affecting the reading of the other chapters. Exposition in the book will be supplemented by illustrations of the usage of R functions in the ‘dferm’ package. While some basic knowledge of R will enhance the reading experience, proficiency in R is not required. Interested readers can find out more information about R from the Comprehensive R Archive Network (CRAN) [83] at

<http://www.r-project.org>.

References

- [1] C. Ahn. An evaluation of phase I cancer clinical trial designs. *Statistics in Medicine*, 17:1537–1549, 1998.
- [2] D. Anbar. Stochastic approximation methods and their use in bioassay and phase I clinical trials. *Communications in Statistics*, 13:2451–2467, 1984.
- [3] M. Ayer, H. D. Brunk, G. M. Ewing, W. T. Reid, and E. Silverman. An empirical distribution function for sampling with incomplete information. *Annals of Mathematical Statistics*, 26:641–647, 1995.
- [4] J. Babb, A. Rogatko, and S. Zacks. Cancer phase I clinical trials: efficient dose escalation with overdose control. *Statistics in Medicine*, 17:1103–1120, 1998.
- [5] D. Bartholomew. Isotonic inference. In *Encyclopedia of Statistical Science: Volume 4*, pages 260–265. New York: Wiley, 1983.
- [6] J. Bartroff and T. L. Lai. Approximate dynamic programming and its applications to the design of phase I cancer trials. *Statistical Science*, 2010 in press.
- [7] R. E. Bechhofer, J. Kiefer, and M. Sobel. *Sequential Identification and Ranking Procedures (with Special Reference to Koopman-Darmois Populations)*. Chicago: University of Chicago Press, 1968.
- [8] B. N. Bekele, Y. Ji, Y. Shen, and P. F. Thall. Monitoring late-onset toxicities in phase I trials using predicted risks. *Biostatistics*, 9:442–457, 2008.
- [9] J. O. Berger. *Statistical Decision Theory and Bayesian Analysis*. New York: Springer-Verlag, 1980.
- [10] J. R. Blum. Multidimensional stochastic approximation methods. *Annals of Mathematical Statistics*, 25:737–744, 1954.
- [11] T. M. Braun. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. *Controlled Clinical Trials*, 23:240–256, 2002.
- [12] T. M. Braun. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. *Statistics in Medicine*, 25:2071–2083, 2006.
- [13] P. P. Carbone, M. J. Krant, S. P. Miller, T. C. Hall, B. I. Shnider, Colsky J., J. Horton, H. Hosley, J. M. Miller, E. Frie, and M. Schneiderman. The feasibility of using randomization schemes early in the clinical trials of new chemotherapeutic agents: Hydroxyurea. *Clinical Pharmacology and Therapeutics*, 6:17–24, 1965.

- [14] J. D. Cheng, J. S. Babb, C. Langer, S. Aamdal, F. Robert, L. R. Engelhardt, O. Fernberg, J. Schiller, G. Forsberg, R. K. Alpaugh, L. M. Weiner, and A. Rogatko. Individualized patient dosing in phase I clinical trials: the role of Escalation With Overdose Control in PNU-214936. *Journal of Clinical Oncology*, 22:602–609, 2004.
- [15] Y. K. Cheung. On the use of nonparametric curves in phase I trials with low toxicity tolerance. *Biometrics*, 58:237–240, 2002.
- [16] Y. K. Cheung. Coherence principles in dose finding studies. *Biometrika*, 92:863–873, 2005.
- [17] Y. K. Cheung. Dose finding with delayed binary outcomes in cancer trials. In S. Chevret, editor, *Statistical Methods for Dose Finding Experiments*, pages 225–242. New York: Wiley, 2006.
- [18] Y. K. Cheung. Sequential implementation of stepwise procedures for identifying the maximum tolerated dose. *Journal of the American Statistical Association*, 102:1448–1461, 2007.
- [19] Y. K. Cheung. Stochastic approximation and modern model-based designs for dose finding clinical trials. *Statist. Sci.*, 25(2):191–201, 2010.
- [20] Y. K. Cheung and R. Chappell. Sequential designs for phase I clinical trials with late-onset toxicities. *Biometrics*, 56:1177–1182, 2000.
- [21] Y. K. Cheung and R. Chappell. A simple technique to evaluate model sensitivity in the continual reassessment method. *Biometrics*, 58:671–674, 2002.
- [22] Y. K. Cheung and M. S. V. Elkind. Stochastic approximation with virtual observations for dose finding on discrete levels. *Biometrika*, 97:109–121, 2010.
- [23] Y. K. Cheung, P. H. Gordon, and B. Levin. Selecting promising ALS therapies in clinical trials. *Neurology*, 67:1748–1751, 2006.
- [24] Y. K. Cheung and P. F. Thall. Monitoring the rates of composite events with censored data in phase II clinical trials. *Biometrics*, 58:89–97, 2002.
- [25] S. Chevret. The continual reassessment method in cancer phase I clinical trials: a simulation study. *Statistics in Medicine*, 12:1093–1108, 1993.
- [26] S. Chevret, editor. *Statistical Methods for Dose Finding Experiments*. New York: Wiley, 2006.
- [27] S. Chevret and S. Zohar. The continual reassessment method. In S. Chevret, editor, *Statistical Methods for Dose Finding Experiments*, pages 131–148. New York: Wiley, 2006.
- [28] C. W. Dunnett and A. C. Tamhane. A step-up multiple test procedure. *Journal of the American Statistical Association*, 87:162–170, 1992.
- [29] S. D. Durham and N. Flournoy. Random walks for quantile estimation. In S.S. Gupta and J.O. Berger, editors, *Statistical Decision Theory and Related Topics V*, pages 467–476. New York: Springer-Verlag, 1994.
- [30] S. D. Durham and N. Flournoy. Up-and-down designs I: Stationery treatment distributions. In N. Flournoy and W. F. Rosenberger, editors, *Adaptive De-*

- signs*, pages 139–157. Hayward, California: Institute of Mathematical Statistics, 1995.
- [31] S. D. Durham, N. Flournoy, and A. A. Montazer-Haghighi. Up-and-down designs II: exact treatment moments. In N. Flournoy and W. F. Rosenberger, editors, *Adaptive Designs*, pages 158–178. Hayward, California: Institute of Mathematical Statistics, 1995.
- [32] S. D. Durham, N. Flournoy, and W. F. Rosenberger. A random walk rule for phase I clinical trials. *Biometrics*, 53:745–760, 1997.
- [33] B. H. Eichhorn and S. Zacks. Sequential search of an optimal dosage, I. *Journal of the American Statistical Association*, 68:594–598, 1973.
- [34] M. S. Elkind, R. L. Sacco, R. B. Macarthur, D. J. Fink, E. Peerschke, H. Andrews, G. Neils, J. Stillman, J. Chong, S. Connolly, T. Corporan, D. Leifer, and K. Cheung. The neuroprotection with statin therapy for acute recovery trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. *International Journal of Stroke*, 3:210–218, 2008.
- [35] V. Fabian. Stochastic approximation of minima with improved asymptotic speed. *Annals of Mathematical Statistics*, 38:191–200, 1967.
- [36] D. Faries. Practical modifications of the continual reassessment method for phase I cancer trials. *Journal of Biopharmaceutical Statistics*, 4:147–164, 1994.
- [37] D. J. Finney. *Statistical Methods in Biological Assay*. Griffin, London, 1978.
- [38] M. Fisher, K. Cheung, G. Howard, and S. Warach. New pathways for evaluating potential acute stroke therapies. *International Journal of Stroke*, 1:52–58, 2006.
- [39] E. Garrett-Mayer. The continual reassessment method for dose finding studies: a tutorial. *Clinical Trials*, 3:57–71, 2006.
- [40] M. Gasparini and J. Eisele. A curve-free method for phase I clinical trials. *Biometrics*, 56:609–615, 2000.
- [41] Constantine Gatsonis and Joel B. Greenhouse. Bayesian methods for phase I clinical trials. *Statistics in Medicine*, 11:1377–1389, 1992.
- [42] W. R. Gilks, S. Richardson, and D. J. Spiegelhalter, editors. *Markov Chain Monte Carlo in Practice*. London: Chapman & Hall, 1996.
- [43] S. N. Goodman, M. L. Zahurak, and S. Piantadosi. Some practical improvements in the continual reassessment method for phase I studies. *Statistics in Medicine*, 14:1149–1161, 1995.
- [44] L. M. Haines, I. Perevozskaya, and W. F. Rosenberger. Bayesian optimal design for phase I clinical trials. *Biometrics*, 59:591–600, 2003.
- [45] J. M. Heyd and B. P. Carlin. Adaptive design improvements in the continual reassessment method for phase I studies. *Statistics in Medicine*, 18:1307–1321, 1998.

- [46] J. C. Hsu and R. L. Berger. Stepwise confidence intervals without multiplicity adjustment for dose-response and toxicity studies. *Journal of the American Statistical Association*, 94:468–482, 1999.
- [47] J. Hüsing, W. Sauerwein, K. Hideghéty, and K. H. Jöckel. A scheme for a dose-escalation study when the event is lagged. *Statistics in Medicine*, 20:3323–3334, 2001.
- [48] A. Iasonos, A. S. Wilton, E. R. Riedel, V. E. Seshan, and D. R. Spriggs. A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in phase I dose finding studies. *Clinical Trials*, 5:465–477, 2008.
- [49] Y. Ji, Y. Li, and B. N. Bekele. Dose finding in phase I clinical trials based on toxicity probability intervals. *Clinical Trials*, 4:235–244, 2007.
- [50] V. R. Joseph. Efficient Robbins-Monro procedure for binary data. *Biometrika*, 91:461–470, 2004.
- [51] H. L. Kaufman, S. Cohen, K. Cheung, G. DeRaffele, J. Mithcam, D. Moroziewicz, J. Schlom, and C. Hesdorffer. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. *Human Gene Therapy*, 17:239–244, 2006.
- [52] J. Kiefer and J. Wolfowitz. Stochastic estimation of the maximum of a regression function. *Annals of Mathematical Statistics*, 23:462–466, 1952.
- [53] E. L. Korn. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. *Journal of National Cancer Institute*, 96:977–978, 2004.
- [54] E. L. Korn, D. Midthune, T. T. Chen, L. V. Rubinstein, M. C. Christian, and R. M. Simon. A comparison of two phase I trial designs. *Statistics in Medicine*, 13:1799–1806, 1994.
- [55] R. Kurzrock and R. S. Benjamin. Risks and benefits of phase I oncology trials, revisited. *New England Journal of Medicine*, 352:930–932, 2005.
- [56] T. L. Lai. Stochastic approximation. *Annals of Statistics*, 31:391–406, 2003.
- [57] T. L. Lai and H. Robbins. Adaptive design and stochastic approximation. *Annals of Statistics*, 7:1196–1221, 1979.
- [58] T. L. Lai and H. Robbins. Consistency and asymptotic efficiency of slope estimates in stochastic approximation schemes. *Zeit Schrift Fur Wahrscheinlichkeitstheorie und Verwandte Gebiete*, 56:329–360, 1981.
- [59] C. Le Tourneau, J. J. Lee, and L. L. Siu. Dose escalation methods in phase I cancer clinical trials. *Journal of the National Cancer Institute*, 101:708–720, 2009.
- [60] S. M. Lee and Y. K. Cheung. Model calibration in the continual reassessment method. *Clinical Trials*, 6:227–238, 2009.
- [61] E. L. Lehmann. *Theory of Point Estimation*. New York: Wiley, 1983.
- [62] J. P. Leonard, R. R. Furman, Y. K. Cheung, E. J. Feldman, H. J. Cho, J. M. Vose, G. Nichols, P. W. Glynn, M. A. Joyce, J. Ketas, J. Ruan, J. Carew,

- R. Niesvizky, A. LaCasce, A. Chadburn, E. Cesarman, and M. Coleman. Phase I/II trial of bortezomib plus CHOP-Rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. *Blood*, 106:147A–147A, 2005.
- [63] D. H. Y. Leung and Y. G. Wang. Isotonic designs for phase I trials. *Controlled Clinical Trials*, 22:126–138, 2001.
- [64] Y. Lin and W. J. Shih. Statistical properties of the traditional algorithm-based designs for phase I cancer trials. *Biostatistics*, 2:203–215, 2001.
- [65] S. M. Lippman, S. E. Benner, and W. K. Hong. Cancer chemoprevention. *Journal of Clinical Oncology*, 12:851–873, 1994.
- [66] P. McCullagh and J. A. Nelder. *Generalized Linear Models*. New York: Chapman & Hall/CRC, 1989.
- [67] S. Møller. An extension of the continual reassessment methods using a preliminary up-and-down design in dose finding study in cancer patients, in order to investigate a greater range of doses. *Statistics in Medicine*, 14:911–922, 1995.
- [68] B. J. T. Morgan. *Analysis of Quantal Response Data*. New York: Chapman & Hall, 1992.
- [69] J. H. Muler, C. J. McGinn, D. Normolle, T. Lawrence, D. Brown, G. Hejna, and M. M. Zalupski. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. *Journal of Clinical Oncology*, 22:238–243, 2004.
- [70] J. R. Murphy and D. L. Hall. A logistic dose-ranging method for phase I clinical investigations trials. *Journal of Biopharmaceutical Statistics*, 7(4):635–647, 1997.
- [71] National Cancer Institute. Common terminology criteria for adverse events. Version 3.0. <http://ctep.cancer.gov/forms/CTCAEv3.pdf>.
- [72] J. Naylor and A. Smith. Applications of a method for the efficient computation of posterior distributions. *Applied Statistics*, 31:214–225, 1982.
- [73] D. Normolle and T. Lawrence. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. *Journal of Clinical Oncology*, 24:4426–4433, 2006.
- [74] J. O’Quigley. Theoretical study of the continual reassessment method. *Journal of Statistical Planning and Inference*, 136:1765–1780, 2006.
- [75] J. O’Quigley and S. Chevret. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. *Statistics in Medicine*, 19:1647–1664, 1991.
- [76] J. O’Quigley, M. D. Hughes, and T. Fenton. Dose finding designs for HIV studies. *Biometrics*, 57:1018–1029, 2001.
- [77] J. O’Quigley, X. Paoletti, and J. MacCario. Non-parametric optimal design in

- dose finding studies. *Biostatistics*, 3:51–6, 2002.
- [78] J. O’Quigley, M. Pepe, and L. Fisher. Continual reassessment method: a practical design for phase I clinical trials in cancer. *Biometrics*, 46:33–48, 1990.
- [79] J. O’Quigley and E. Reiner. A stopping rule for the continual reassessment method. *Biometrika*, 85:741–748, 1998.
- [80] J. O’Quigley and L. Z. Shen. Continual reassessment method: a likelihood approach. *Biometrics*, 52:673–684, 1996.
- [81] S. Piantadosi, J. D. Fisher, and S. A. Grossman. Practical implementation of the continual reassessment method for dose finding trials. *Cancer Chemotherapy and Pharmacology*, 41:429–436, 1998.
- [82] M.-Y. Polley and Y. K. Cheung. Two-stage designs for dose finding trials with a biologic endpoint using stepwise tests. *Biometrics*, 64:232–241, 2008.
- [83] R Development Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL <http://www.r-project.org>, 2008.
- [84] M. J. Ratain, D. Collyar, B. Kamen, E. Eisenhauer, T. S. Lawrence, C. Runowicz, S. Turner, and J. L. Wade. Critical role of phase I clinical trials in cancer treatment. *Journal of Clinical Oncology*, 15:853–859, 1997.
- [85] M. J. Ratain, R. Mick, R. L. Schilsky, and M. Siegler. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. *Journal of the National Cancer Institute*, 85:1637–1643, 1993.
- [86] H. Robbins and S. Monro. A stochastic approximation method. *Annals of Mathematical Statistics*, 22:400–407, 1951.
- [87] H. Robbins and D. Siegmund. A convergence theorem for non-negative almost supermartingales and some applications. In Jagdish S. Rustagi, editor, *Optimizing Methods in Statistics*, pages 233–257. Academic Press, New York, 1971.
- [88] A. Rogatko, D. Schoeneck, W. Jonas, M. Tighiouart, F. R. Khuri, and A. Porter. Translation of innovative designs into phase I trials. *Journal of Clinical Oncology*, 25:4982–4986, 2007.
- [89] D. D. Rosa, J. Harris, and G. C. Jayson. The best guess approach to phase I trial design. *Journal of Clinical Oncology*, 24:206–208, 2006.
- [90] J. Ruan, P. Martin, R. R. Furman, S. M. Lee, K. Cheung, J. M. Vose, A. LaCasce, J. Morrison, R. Elstrom, S. Ely, A. Chadburn, E. Cesarman, M. Coleman, and J. P. Leonard. Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). *Journal of Clinical Oncology*, 2010 under review.
- [91] D. B. Rubin. Inference and missing data. *Biometrika*, 63:581–592, 1976.
- [92] J. Sacks. Asymptotic distribution of stochastic approximation procedures. *Annals of Mathematical Statistics*, 29:373–405, 1958.

- [93] M. A. Schneiderman. How can we find an optimal dose? *Toxicology and Applied Pharmacology*, 7:44–53, 1965.
- [94] L. Z. Shen and J. O’Quigley. Consistency of continual reassessment method under model misspecification. *Biometrika*, 83:395–405, 1996.
- [95] L. Z. Shen and J. O’Quigley. Using a one-parameter model to sequentially estimate the root of a regression function. *Computational Statistics and Data Analysis*, 34:357–369, 2000.
- [96] M. J. Silvapulle. On the existence of maximum likelihood estimators for the binomial response model. *Journal of the Royal Statistical Society Series B*, 43:310–313, 1981.
- [97] B. Storer and D. DeMets. Current phase I/II designs: Are they adequate? *Journal of Clinical Research and Drug Development*, 1:121–130, 1987.
- [98] B. E. Storer. Design and analysis of phase I clinical trials. *Biometrics*, 45:925–937, 1989.
- [99] M. Stylianou and N. Flournoy. Dose finding using the biased coin up-and-down design and isotonic regression. *Biometrics*, 58:171–177, 2002.
- [100] A. C. Tamhane, Y. Hochberg, and C. W. Dunnett. Multiple test procedures for dose finding. *Biometrics*, 52:21–37, 1996.
- [101] J. Tang and A. K. Gupta. On the distribution of the produce of independent beta variables. *Statistics and Probability Letters*, 2:165–168, 1984.
- [102] P. F. Thall and J. D. Cook. Dose finding based on efficacy–toxicity trade-offs. *Biometrics*, 60:684–693, 2004.
- [103] P. F. Thall, J. J. Lee, C. H. Tseng, and E. H. Estey. Accrual strategies for phase I trials with delayed patient outcome. *Statistics in Medicine*, 18:1155–1169, 1999.
- [104] P. F. Thall, H. Nguyen, and E. H. Estey. Patient-specific dose finding based on bivariate outcomes and covariates. *Biometrics*, 64:1126–1136, 2008.
- [105] N. Ting, editor. *Dose Finding in Drug Development (Statistics for Biology and Health)*. Berlin: Springer, 2006.
- [106] J. M. Treluyer, S. Zohar, E. Rey, P. Hubert, F. Iserin, M. Jugie, R. Lenclen, S. Chevret, and G. Pons. A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. *Biometrics*, 54:251–264, 1998.
- [107] J. H. Venter. An extension of the Robbins-Monro procedure. *Annals of Mathematical Statistics*, 38:181–190, 1967.
- [108] A. Wald. Sequential tests of statistical hypotheses. *Annals of Mathematical Statistics*, 16:117–186, 1945.
- [109] A. Wald and J. Wolfowitz. Optimum character of the sequential probability ratio test. *Annals of Mathematical Statistics*, 19:326–339, 1948.
- [110] G. B. Wetherill. Sequential estimation of quantal response curves. *Journal of the Royal Statistical Society, Series B*, 25:1–48, 1963.

- [111] J. Whitehead and H. Brunier. Bayesian decision procedures for dose determining experiments. *Statistics in Medicine*, 14:885–893, 1995.
- [112] C. F. J. Wu. Efficient sequential designs with binary data. *Journal of the American Statistical Association*, 80:974–84, 1985.
- [113] C. F. J. Wu. Maximum likelihood recursion and stochastic approximation in sequential designs. In Van Ryzin, editor, *Adaptive Statistical Procedures and Related Topics*, volume 8, pages 298–313. Institute of Mathematical Statistics, 1986.
- [114] X. Wu. Stepwise procedures for dose finding in an adaptive clinical trial of early rehabilitation after acute stroke. In *DrPH dissertation*. Columbia University, 2010.
- [115] G. Yin, Y. Li, and Y. Ji. Bayesian dose finding in phase I/II clinical trials using toxicity and efficacy odds ratio. *Biometrics*, 62:777–787, 2006.
- [116] Z. Ying and C. F. J. Wu. An asymptotic theory of sequential designs based on maximum likelihood recursion. *Statistica Sinica*, 7:75–91, 1997.
- [117] S. Zacks, A. Rogatko, and J. Babb. Optimal bayesian-feasible dose escalation for cancer phase I trials. *Statistics and Probability Letters*, 38:215–220, 1998.

Statistics

As clinicians begin to realize the important role of dose finding in the drug development process, there is an increasing openness to “novel” methods proposed in the past two decades. In particular, the Continual Reassessment Method (CRM) and its variations have drawn much attention in the medical community, though it has yet to become a commonplace tool. To overcome the status quo in phase I clinical trials, statisticians must be able to design trials using the CRM in a timely and reproducible manner.

A self-contained theoretical framework of the CRM for researchers and graduate students who set out to learn and do research in the CRM and dose finding methods in general, **Dose Finding by the Continual Reassessment Method** features:

- Real clinical trial examples that illustrate the methods and techniques throughout the book
- Detailed calibration techniques that enable biostatisticians to design a CRM in timely manner
- Limitations of the CRM are outlined to aid in correct use of method

This book supplies practical, efficient dose finding methods based on cutting edge statistical research. More than just a cookbook, it provides full, unified coverage of the CRM in addition to step-by-step guidelines to automation and parameterization of the methods used on a regular basis. A detailed exposition of the calibration of the CRM for applied statisticians working with dose finding in phase I trials, the book focuses on the R package ‘dform’ for the CRM and its major variants.

The author recognizes clinicians’ skepticism of model-based designs and addresses their concerns that the time, professional, and computational resources necessary for accurate model-based designs can be major bottlenecks to the widespread use of appropriate dose-finding methods in phase I practice. The theoretically- and empirically-based methods in **Dose Finding by the Continual Reassessment Method** will lessen the statistician’s burden and encourage the continuing development and implementation of model-based dose finding methods.



CRC Press

Taylor & Francis Group
an informa business

www.crcpress.com

6000 Broken Sound Parkway, NW
Suite 300, Boca Raton, FL 33487

270 Madison Avenue
New York, NY 10016

2 Park Square, Milton Park
Abingdon, Oxon OX14 4RN, UK

C9151

ISBN: 978-1-4200-9151-9



9 781420 091519